Using linked HIV observational patient level databases to examine risk for and outcome of maternal HIV infection

今天，在英国，只有约1%的确诊艾滋病毒阳性孕妇将艾滋病毒传染给她们的婴儿，这主要归功于抗艾滋病毒药物的“药物鸡尾酒”的使用。需要进行研究，以改进我们对艾滋病毒阳性孕妇的管理，特别是在艾滋病毒阳性孕妇的人口以及所使用的药物类型正在发生变化的情况下。尽管有好处，但人们仍然担心怀孕期间服用抗艾滋病毒药物的安全性，例如，早产的可能性似乎增加了。一些抗艾滋病毒药物会导致动物癌症，但出生前接触抗艾滋病毒药物的艾滋病毒阴性儿童的长期健康后果尚不确定。我们计划通过分析英国和爱尔兰孕期和儿童艾滋病毒国家研究的数据，在管理和安全方面调查这些问题，该研究收集了所有确诊的艾滋病毒阳性孕妇及其婴儿的信息。为了调查出生前接触抗艾滋病毒药物可能产生的长期不良后果，我们计划发展我们的研究数据与其他健康信息来源的联系。该项目的成果将对艾滋病毒阳性妇女、她们的医生和卫生保健规划者具有重要意义，并应有助于改善对艾滋病毒阳性孕妇及其子女的管理。

In the UK today only ~1% of diagnosed HIV-positive pregnant women pass on HIV to their babies, mainly thanks to the use of "drug cocktails" of anti-HIV drugs. Research is needed to improve our management of HIV-positive pregnant women, particularly as the population of HIV-positive pregnant women is changing, as well as the types of drugs used. Despite their beneficial effects, concerns remain about the safety of taking anti-HIV drugs in pregnancy, for example there appears to be an increased chance of giving birth prematurely. Some anti-HIV drugs cause cancer in animals, but long-term health consequences for HIV-negative children exposed to anti-HIV drugs before birth are uncertain. We plan to investigate these issues in management and safety by analysing data from the UK and Ireland National Study of HIV in Pregnancy and Childhood, which collects information on all diagnosed HIV-positive pregnant women and their babies. To investigate possible long-term adverse consequences of exposure to anti-HIV drugs before birth, we plan to develop our linkage of Study data with other sources of health information. The project results will be important for HIV-positive women, their doctors and health care planners and should help improve management of HIV-positive pregnant women and their children.